FIG 2.

Enzalutamide efficacy in patients with AR+ SGC. (A) Waterfall plot of best percent change in tumor size from baseline by best response and prior AR-targeted therapy. (B) Swimmer's plot by prior AR targeted therapy and outcome. (C) KM curve of PFS. (D) KM curve of OS. ^aThough reduction of target lesions met PR criteria, this patient had a BOR of PD due to the appearance of a new tumor. AR, androgen receptor; BOR, best overall response; KM Est, Kaplan-Meier estimates; OS, overall survival; PD, disease progression; PFS, progression-free survival; PR, partial response; SD, stable disease; SGC, salivary gland cancer.